share_log

Baird Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $54

Baird Initiates Coverage On Neurogene With Outperform Rating, Announces Price Target of $54

貝爾德初始覆蓋神經基因公司,給予跑贏大市評級,宣佈54美元的目標價格。
Benzinga ·  06/11 05:18

Baird analyst Joel Beatty initiates coverage on Neurogene (NASDAQ:NGNE) with a Outperform rating and announces Price Target of $54.

Baird分析師喬爾·貝蒂(Joel Beatty)發起對神經遺傳公司(NASDAQ:NGNE)的覆蓋,並宣佈目標價格爲54美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論